Biomarin Pharmaceutical (BMRN) Research & Development (2009 - 2026)

Biomarin Pharmaceutical (BMRN) has 18 years of Research & Development data on file, last reported at $178.8 million in Q1 2026.

• Quarterly Research & Development rose 12.64% year-over-year to $178.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $942.0 million (up 34.39% YoY) and the FY2025 annual result came in at $921.9 million, up 23.39% from the prior year.
• Research & Development fell to $178.8 million in Q1 2026, from $192.4 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $409.5 million in Q3 2025 to a low of $157.8 million in Q3 2022.
• A 5-year average of $190.8 million and a median of $177.4 million in 2023 frame the typical range for Research & Development.
• The widest YoY moves for Research & Development: up 121.46% in 2025, down 22.57% in 2025.
• Tracing BMRN's Research & Development over 5 years: stood at $172.8 million in 2022, then grew by 19.39% to $206.2 million in 2023, then fell by 15.87% to $173.5 million in 2024, then grew by 10.9% to $192.4 million in 2025, then retreated by 7.08% to $178.8 million in 2026.
• The last three Research & Development figures came in at $178.8 million (Q1 2026), $192.4 million (Q4 2025), and $409.5 million (Q3 2025), per Business Quant data.